Inspira Technologies Oxy B.H.N. Ltd. reports developments in Additively Manufactured Electronics, quantum connectivity and its medical technology portfolio. Company updates focus on AME system orders and deployments, QTREX-branded cryogenic interconnect work for superconducting quantum systems, customer activity with research, defense and technology organizations, and leadership or strategic-direction announcements.
The company's medical technology context includes respiratory support and blood monitoring platforms, including INSPIRA ART, INSPIRA ART100 and the HYLA Blood Sensor, while recent communications emphasize a dedicated medical business unit alongside the AME and quantum connectivity strategy.
Inspira Technologies OXY B.H.N. Ltd has successfully closed its initial public offering (IPO) of 2,909,091 units at a price of $5.51 per unit, generating approximately $16 million in gross proceeds. Each unit includes one ordinary share and one warrant. The company has granted Aegis Capital Corp. a 45-day option for additional shares and warrants. The shares and warrants are now trading on Nasdaq under symbols IINN and IINNW respectively. Notably, Inspira's Augmented Respiration Technology is still pending FDA approval and human testing.
Inspira Technologies OXY B.H.N. Ltd announced the pricing of its initial public offering (IPO) of 2,909,091 common units, priced at $5.51 each, comprising one ordinary share and one warrant per unit. The offering is expected to raise $16 million in gross proceeds and is set to close on July 16, 2021, subject to customary conditions. Additionally, Aegis Capital Corp. has a 45-day option to purchase up to 15% more common units to cover over-allotments. Trading on Nasdaq is expected to begin on July 14, 2021 under the symbols IINN and IINNW.